REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to eight new employees. The independent members of the Board of Directors of […]
Category Archives: Pr Newswire
Almost half (45%) of workers say their workload has increased significantly in the past year, as almost two-thirds (62%) say the pace of change at work has increased over the same time More than one-quarter (28%) say they are very or extremely likely to switch employer in the next 12 months – a higher proportion […]
CANGZHOU, China, June 25, 2024 /PRNewswire/ — The year 2024 marked the 10th anniversary of Grand Canal’s UNESCO world heritage listing. The success of the application has revitalized the Grand Canal, which is a recognition of its historical value and an expectation for its future protection and development. Cangzhou, Hebei Province, has achieved fruitful results […]
A Science-Based Approach Will Determine if the Species is Truly ‘Endangered’ WASHINGTON, June 25, 2024 /PRNewswire/ — The National Association for Biomedical Research (NABR) commends the Union for the Conservation of Nature (IUCN)’s decision to reassess the ‘Endangered’ designation of long-tailed macaque monkeys (macaca fascicularis). “NABR is pleased that the IUCN will reassess its designation […]
Addressing the signal range challenge of many Beyond 5G networks, antenna and low-earth orbit satellite expert is facilitating adoption of 5G NTN in smaller private networks TOKYO and TAIPEI, June 25, 2024 /PRNewswire/ — As mobile communications speeds grow and Beyond 5G and 6G networks develop, signal range and coverage are growing challenges — and […]
SYDNEY, June 25, 2024 /PRNewswire/ — Emphasys Pty Ltd, a pioneer in SAP services and solutions, proudly announces its newly awarded Gold Partnership with Informatica, a leader in enterprise data management. This significant milestone underscores Emphasys’s commitment to delivering unparalleled data management solutions across Australia, the Asia Pacific, and Europe. Founded by a team of […]
Pr Newswire
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
24
Jun
Jun
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health […]
Pr Newswire
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
24
Jun
Jun
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce […]
Pr Newswire
Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis
24
Jun
Jun
– Campaign to elevate experiences from the recurrent pericarditis community and provide resources to patients and caregivers – HAMILTON, Bermuda, June 24, 2024 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced a […]
24
Jun
Jun
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its underwritten public offering of 11,250,000 shares of its common stock at a price to the public of $4.00 per share and, […]